Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine

Annals of the New York Academy of Sciences

Volumn 1263, Issue 1, 2012, Pages 15-26

  Gruber, William C ^a   Scott, Daniel A ^a   Emini, Emilio A ^a  

^a PFIZER INC   (United States)

Author keywords

Children; Conjugate; Infants; Pneumococcal; Pneumococcus; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; DIPHTHERIA TOXOID CRM197; PNEUMOCOCCUS VACCINE; PREVNAR 7; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; CHILD; CHRONIC OTITIS MEDIA; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; INCIDENCE; INTRACELLULAR KILLING; LICENSING; MASTOIDITIS; META ANALYSIS (TOPIC); MOLECULAR RECOGNITION; MORTALITY; NEISSERIA MENINGITIDIS; OPSONIZATION; PATIENT SATISFACTION; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTYPE; STREPTOCOCCUS PNEUMONIA; TODDLER; TYMPANOSTOMY TUBE; UNITED STATES;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 84864780917     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06673.x     Document Type: Article

References (84)

1. WHO. 2004. Global Immunization Data. Available at: Accessed July 11, 2008.
2. Gray, B.M. & D.M. Musher. 2008. The history of pneumococcal disease. In Pneumococcal Vaccines. The Impact of Conjugate Vaccine. G.R. Siber, K.P. Klugman & P.H. Mäkela, Eds.: 3-17. ASM Press. Washington, DC.
3. Kim, J.O., S. Romero-Steiner, U.B. Sorensen, et al. 1999. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumonia. Infect. Immun. 67: 2327-2333.
4. Pilishvili, T., C. Lexau, M.M. Farley, et al. 2010. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201: 32-41.
5. Frenck, R.W. & S. Yeh. 2012. The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opin. Biol. Ther. 12: 63-77.
6. Paradiso, P.A. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin. Infect. Dis. (in press).
7. Schuchat, A., K. Robinson, J.D. Wenger, et al. 1997. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N. Engl. J. Med. 337: 970-976.
8. Whitney, C.G., M.M. Farley, J. Hadler, et al. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348: 1737-1746.
9. Robinson, K.A., W. Baughman, G. Rothrock, et al. 2001. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285: 1729-1735.
10. Chavez-Bueno, S. & G.H. McCracken, Jr. 2005. Bacterial meningitis in children. Pediatr. Clin. North Am. 52: 795-810, vii.
11. Pelton, S.I. 2003. Otitis media. In Principles and Practice of Pediatric Infectious Diseases, 2nd Ed. S.S. Long, L.K. Pickering & C.G. Prober, Eds.: 190-198. Churchill Livingstone. New York.
12. Metchnikoff, E. 1891. Études sur l'immunité, 4e mémoire. L'immunité de cobayes vaccinés contre le vibrio Metchnikowii. Ann. Inst. Pasteur. 5: 465-478.
13. Neufeld, F. 1902. Ueber die agglutination de pneumockokken und über die theorieen der agglutination. Z. Hyg. Infectkrankh. 34: 454-464.
14. Felton, L.D. & G.H. Bailey. 1926. The specific precipitates obtained from antipneumococcus serum and antibody solution by the soluble specific substance of pneumococcus. J. Infect Dis. 38: 145-164.
15. Ward, H.K. & J.F. Enders. 1933. An analysis of the opsonic and tropic action of normal and immune sera based on experiments with the pneumococcus. J. Exp. Med. 57: 527-547.
16. Feavers, I., I. Knezevic, M. Powell & E. Griffiths. 2009. WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 27: 3681-3688.
17. MacLeod, C.M., R.G. Hodges, M. Heidelberger & W.G. Bernhard. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82: 445-466.
18. Smit, P., D. Oberholzer, S. Hayden-Smith, et al. 1977. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 238: 2613-2616.
19. Austrian, R., R.M. Douglas, G. Schiffman, et al. 1976. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 89: 184-194.
20. Douglas, R., J. Paton, S. Duncan & D. Hansman. 1983. Antibody response to pneumococcoal vaccination in children younger than five years of age. J. Infect. Dis. 148: 131-137.
21. Sell, S., P. Wright, W. Vaught, et al. 1981. Clinical studies of pneumococal vaccine in infants. 1. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev. Infect. Dis. 3: S97-S107.
22. Harding, C.V., W. Roof, P.M. Allen & E.R. Unanue. 1991. Effects of pH and polysaccharides on peptide binding to class I major histocompatibility complex molecules. Proc. Natl. Acad. Sci. USA 88: 2740-2744.
23. Ishioka, G.Y., A.G. Lamont, D. Thomson, et al. 1992. MHC interaction and T cell recognition of carbohydrates and glycopeptides. J. Immunol. 148: 2446-2451.
24. Goldblatt, D., T. Assari & C. Snapper. 2008. The immunobiology of polysaccharide and conjugate vaccines. In Pneumococcal Vaccines. The Impact of Conjugate Vaccine. G.R. Siber, K.P. Klugman & P.H. Makela, Eds.: 67-82. ASM Press. Washington, DC.
25. Avery, O.T. Goebel. 1931. Chemo-immunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type II pneumocococcus with foreign protein. J. Exp. Med. 54: 419-426.
26. Active Bacterial Core Surveillance. U.S. Centers for Disease Control and Prevention. Accessed March 21, 2012.
27. Haemophilus Influenzae: Epidemiological Data. Health Protection Agency, UK. Accessed March 21, 2012.
28. Meningococcal Disease: Epidemiological Data. Health Protection Agency, UK. Accessed March 12, 2012.
29. Black, S., H. Shinefield, B. Fireman, et al. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19: 187-195.
30. Black, S.B., H.R. Shinefield, S. Ling, et al. 2002. Efficacy of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21: 810-815.
31. Hansen, J., S. Steven, H. Shinefield, et al. 2006. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia. Updated Analysis Using World Health Organization Standardized Interpretation of Chest Radiographs. Pediatr. Infect. Dis. J. 25: 779-781.
32. Fireman, B., S.B. Black, H.R. Shinefield, et al. 2003. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22: 10-16.
33. Eskola, J., T. Kilpi, J. Jokinen, et al. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344: 403-409.
34. O'Brien, K., L. Moulton, R. Reid, et al. 2003. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362: 355-361.
35. Watt, J.P., K.L. O'Brien, A.L. Benin, et al. 2004. Invasive pneumococcal disease among Navajo adults, 1989-1998. Clin. Infect. Dis. 38: 496-501.
36. Klugman, K.P., S.A. Madhi, R.E. Huebner, et al. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349: 1341-1348.
37. Cutts, F.T., S.M. Zaman, G. Enwere, et al. 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. Lancet 365: 1139-1146.
38. Pneumococcal Vaccine Support. GAVI Alliance. Accessed March 18, 2012.
39. Grijalva, C.G., J.P. Nuorti, P.G. Arbogast, et al. 2007. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369: 1179-1186.
40. Nelson, J.C., M. Jackson, O. Yu, et al. 2008. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 26: 4947-4954.
41. Grijalva, C.G., K.A. Poehling, J.P. Nuorti, et al. 2006. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118: 865-873.
42. Poehling, K.A., P.G. Szilagyi, C.G. Grijalva, et al. 2007. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119: 707-715.
43. Zhou, F., A. Shefer, Y. Kong & J.P. Nuorti. 2008. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121: 253-260.
44. 2005. Direct and indirect effects of routine vaccination of children with 7-Valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. Morb. Mortal. Wkly. Rep. 54: 893-897.
45. Hausdorff, W.P. 2007. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 25: 2406-2412.
46. Byington, C.L., M.H. Samore, G.J. Stoddard, et al. 2005. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin. Infect. Dis. 41: 21-29.
47. Byington, C.L., K. Korgenski, J. Daly, et al. 2006. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J. 25: 250-254.
48. Bender, J.M., K. Ampofo, K. Korgenski, et al. 2008. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin. Infect. Dis. 46: 1346-1352.
49. Kyaw, M.H., R. Lynfield, W. Schaffner, et al. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354: 1455-1463.
50. Kaplan, S.L., W. Barson, P. Lin, et al. 2010. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 125: 429-436.
51. Pelton, S.I., H. Huot, J.A. Finkelstein, et al. 2007. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26: 468-472.
52. 2007. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae- Massachusetts, 2001-2006. Morb. Mortal. Wkly. Rep. 56: 1077-1080.
53. Messina, A.F., K. Katz-Gaynor, T. Barton, et al. 2007. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J. 26: 461-467.
54. Hausdorff, W.P., G. Siber & P.R. Paradiso. 2001. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357: 950-952.
55. McIntosh, E.D., B. Fritzell & M.A. Fletcher. 2007. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol. Infect. 135: 644-656.
56. Gupta, R.K., B.E. Rost, E. Relyveld & G.R. Siber. 1995. Adjuvant properties of aluminum and calcium compounds. In Vaccine Design: The Subunit and Adjuvant Approach. M.F. Powell & M.J. Newman, Eds.: 237-238. Plenum Press. New York.
57. HogenEsch, H. 2002. Mechanism of stimulation of the immune response by aluminum adjuvants. Vaccine 20: S34-S39.
58. World Health Organization. Pneumococcal conjugate vaccines: recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series, No. 927, 2005, Annex 2. Available at: Accessed 27 October 2008.
59. Jodar, L., J. Butler, G. Carlone, et al. 2003. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21: 3265-3272.
60. Siber, G.R., I. Chang, S. Baker, et al. 2007. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25: 3816-3826.
61. Scott, D.A., S.F. Komjathy, B.T. Hu, et al. 2007. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25: 6164-6166.
62. Bryant, K.A., S.L. Block, S.A. Baker, et al., Group PCVIS. 2010. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 125: 866-875.
63. Yeh, S.H., A. Gurtman, D.C. Hurley, et al. 2010. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 126: e493-505
64. Kieninger, D.M., K. Kueper, K. Steul, et al. 2010. Study G. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28: 4192-203.
65. Esposito, S., S. Tansey, A. Thompson, et al. 2010. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin. Vaccine Immunol. 17: 1017-1026.
66. Gadzinowski, J., P. Albrecht, B. Hasiec, et al. 2011. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine 29: 2947-2955.
67. Gimenez-Sanchez, F., D.M. Kieninger, K. Kueper, et al. 2011. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine 29: 6042-6048.
68. Payton, T., D. Girgenti, R. Frenck, et al. Safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccination. Presented at the 2nd Vaccine Global Congress, Boston, MA, USA, 7-9 December 2008.
69. Vanderkooi, O.G., D.W. Scheifele, D. Girgenti, et al. for the Canadian PCV13 Study Group. 2012. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr. Inf. Dis. J. 31: 72-77.
70. Wysocki, J., E.D. Daniels, D.A. Sarkozy, et al. Presented at the 27th Annual Meeting of the European Society for Pediatric Infectious Disease (ESPID), June 9-13, 2009, Brussels, Belgium.
71. Grimprel, E., F. Laudat, S. Patterson, et al. 2011. Immunogenicity and seafter of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine 29: 9675-9683.
72. Frenck, R., A. Thompson, S.H. Yeh, et al. 2011. Imunogenicity and safety of a 13-valent pneumocaoccal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. Pediatr. Inf. Dis. J. 30: 1086-1091.
73. Black, S. & H. Shinefield. 2002. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur. J. Pediatr. 161(Suppl 2): S127-S131.
74. Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) 30 Wyeth Pharmaceuticals, Inc (Prevnar 13). Vaccines, Blood, and Biologics. U.S. Food and Drug Administration. Accessed March 29, 2012.
75. Wise, R.P, J. Iskander, R.D. Pratt, et al. 2004. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 292: 1702-1710.
76. Sponsor Pre-Meeting Package, Prevnar13, VRBPAC, FDA, November 18, 2009, pp 154-211.
77. Miller, E., N.J. Andrews, P.A. Waight, et al. 2011. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29: 9127-9131.
78. Singleton, R.J., T.W. Hennessy, L.R. Bulkow, et al. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784-1792.
79. Wenger, J.D., T. Zulz, D. Bruden, et al. 2010. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr. Infect. Dis. J. 29: 251-256.
80. Cooper, D., X. Yu, M. Sidhu, et al. 2011. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 29: 7207-7211.
81. Sjostrom, K., C. Spindler, A. Ortqvist, et al. 2006. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin. Infect. Dis. 42: 451-459.
82. Alanee, S.R., L. McGee, D. Jackson, et al. 2007. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin. Infect. Dis. 45: 46-51.
83. Weinberger, D.M., Z.B. Harboe, E.A. Sanders, et al. 2010. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin. Infect. Dis. 51: 692-699.
84. Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers. ClinicalTrials.gov. Accessed March 21, 2012.